SIGA Technologies
New York
About SIGA Technologies
SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $190.6M
- Funding stage: IPO
- Last round: Grant (Jun 2020)
- Ticker: nasdaq:SIGA
- Website: siga.com
- Phone: +1 212.672.9100
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/siga-technologies-176499 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.